-  INCLUSION CRITERIA:

        Inclusion Criteria: Recipient

          1. Recipients (patients with B-cell malignancy) must have received an HLA-identical or
             9/10 matched sibling allogeneic hematopoietic stem cell transplant, a 1-antigen
             mismatched related transplant, or a greater than or equal to 9/10-matched unrelated
             donor (URD) alloHSCT for any CD19+ B-cell malignancy. Patients with any CD19+ B-cell
             malignancy that is persistent or relapsed after all of the following interventions are
             eligible:

               1. Donor T cell engraftment after alloHSCT (>50% donor chimerism of the T cell
                  compartment and a peripheral blood T cell number from the NIH, CC clinical lab of
                  at least 50 CD3+ cells/uL).

               2. A trial of withdrawal of immunosuppressive therapy.

             Exception: Prior (DCI) DLI is not an eligibility requirement for patients with ALL,
             Burkitt lyphoma, ALL like high-grade lymphomas, or diffuse large B-cell lymphoma.

             At least 28 days weeks must have elapsed since the latest trial of withdraw of
             immunosuppression or DLI until the patient can be deemed to have persistent disease.

          2. CD19 expression must be detected on the majority of the malignant cells by
             immunohistochemistry or by flow cytometry in the Laboratory of Pathology, CCR, NCI,
             NIH. Definition of which cells are malignant must be determined for each patient by
             the Laboratory of Pathology using techniques to demonstrate monoclonality such as
             kappa/lambda restriction (other techniques can be used to determine monoclonality at
             the discretion of the Laboratory of Pathology). The choice of whether to use flow
             cytometry or immuohistochemistry will be determined by what is the most easily
             available tissue sample in each patient. Immunohistochemistry will be used for lymph
             node biopsies and bone marrow biopsies. Flow cytometry will be used for peripheral
             blood, fine needle aspirate, and bone marrow aspirate samples.

          3. Patients must be 18-75 years of age.

          4. Performance status: ECOG less than or equal to 2

          5. Either no evidence of GVHD or minimal clinical evidence of acute GVHD and chronic GVHD
             while off of systemic immunosuppressive therapy for at least 28 days. Minimal clinical
             evidence of acute GVHD is defined as grade 0 to I acute GVHD. Minimal evidence of
             chronic GVHD is defined as chronic GVHD with no organ site with a score exceeding 1,
             except for the skin, for which a score of 1 or 2 will be allowable (as defined by the
             2005 NIH consensus project) or no chronic GVHD. Subjects with disease that is
             controlled to stage I acute GVHD or chronic GVHD meeting the above criteria with local
             therapy only, e.g., topical cutaneous steroids, will be eligible for enrollment.

          6. Ability to give informed consent.

          7. Prior Therapy: Therapy with monoclonal antibodies and/or chemotherapy must be stopped
             at least 7 days prior to anti-CD19 CAR-transduced T cell infusion, and recovery of
             treatment-associated toxicity to less than or equal to grade 2 is required prior to
             infusion of cells. For patients that have received prior DLI, the last dose must be at
             least 28 days prior to anti-CD19 CAR-transduced T cell administration. Note that
             patients can be enrolled on this study at any time after or during therapy, but at
             least 14 days must elapse from the time of prior monoclonal antibody administration or
             chemotherapy until anti-CD19 CAR-transduced T cells are infused, and at least 28 days
             must elapse from the time of withdraw of immunosuppression, or DLI, or other
             immunomodulatory therapies such as lenalidomide until anti-CD19 CAR-transduced T cells
             are infused. Systemic immunosuppression given for graft versus host disease must be
             stopped at least 28 days prior to protocol entry. There is no time restriction in
             regard to prior intrathecal chemotherapy provided there is complete recovery from any
             acute toxic effects of such.

          8. Recipients of unrelated donor transplants from a National Marrow Donor Program (NMDP)
             Center must sign a release of information form to authorize NMDP transfer of
             information to the NIH.

          9. Previous allogeneic donor must be willing and available to donate again.

         10. Patients of childbearing or child-fathering potential must be willing use an effective
             method of contraception while being treated on this study and for 4 months after the
             last cell infusion.

         11. Normal left ventricular function as evaluated by echocardiograph within 4 weeks of
             anti- CD19-CAR-transduced T cell infusion

        Inclusion Criteria: Donor

          1. Donors greater than or equal to 18 years of age must be the same individual whose
             cells were used as the source for the patient s original stem cell transplant.

          2. Adequate venous access for peripheral leukapheresis, or consent to use a temporary
             central venous catheter for leukapheresis.

          3. Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C
             antibody negative.

          4. Ability to give informed consent.

          5. Donor selection will be in accordance with NIH/CC Department of Transfusion Medicine
             (DTM) criteria and, in the case of an unrelated donor from a Transplant Center, the
             National Marrow Donor Program (NMDP) standards. When a potentially eligible recipient
             of an unrelated donor product from an NMDP Center is identified, the recipient will
             complete an NMDP search transfer request to allow NIH NMDP staff to contact the NMDP
             Coordinating Center, who will, in turn, contact the donor s prior Donor Center. The
             NMDP Policy for Subsequent Donation Requests will be followed and the appropriate
             forms (Subsequent Donation Request form) and Therapeutic T Cell Collection
             Prescription will be submitted as required.

        EXCLUSION CRITERIA:

        Exclusion Criteria: Recipients

          1. Active infection that is not responding to antimicrobial therapy.

          2. Sero positive for HIV antibody. (The experimental treatment being evaluated in this
             protocol depends on an intact immune system. Patients who are HIV seropositive can
             have decreased immune -competence and thus are less responsive to the experimental
             treatment and more susceptible to its toxicities.)

          3. Sero positive for hepatitis B antigen, positive hepatitis B tests can be further
             evaluated by confirmatory tests (HBV DNA), and if confirmatory tests are negative, the
             patient can be enrolled.

          4. Sero positive for hepatitis C antibody unless antigen negative. If hepatitis C
             antibody test is positive, then patients must be tested for the presence of RNA by
             RT-PCR and be HCV RNA negative.

          5. Active psychiatric disorder which may compromise compliance with the treatment
             protocol, or which does not allow for appropriate informed consent (as determined by
             Principal Investigator and/or his designee).

          6. Pregnant or lactating. The effects of the immunosuppressive medications that could be
             required to treat GHVD are likely to be harmful to a fetus. The effects upon breast
             milk are also unknown and may be harmful to an infant.

          7. Serum total bilirubin > 2.5 mg/dl, serum ALT and AST values greater than or equal to
             2.5 times the upper limit of normal based on age-specific normal values. If the
             abnormal liver function is attributable to liver involvement by malignancy, patients
             may be eligible with serum total bilirubin up to 5.0 mg/dl, and serum ALT and AST
             values up to 5.0 times the upper limit of normal, provided the patient has no evidence
             of impending hepatic failure (encephalopathy or prothrombin time >2 times the upper
             limit of normal).

          8. Serum creatinine greater than 1.6 mg/dL

          9. Absolute neutrophil count of less than 1000 cells/microL unless low neutrophil count
             is thought to be due to malignancy in the bone marrow and malignancy is documented in
             the bone marrow.

         10. Active cerebrospinal fluid involvement with malignancy or brain metastasis.

         11. Platelet count less than 30,000/microL unless low platelet count is thought to be due
             to malignancy in the bone marrow and malignancy is documented in the bone marrow.

         12. Hemoglobin less than 8.0 g/dL.

         13. Receiving systemic corticosteroids including prednisone, dexamethasone or any other
             corticosteroid at doses of higher than 5 mg/day of prednisone within 28 days prior to
             anti-CD19-CAR-transduced T cell administration. Corticosteroid creams, ointments, and
             eye drops are allowed.

         14. Blood blast percentage higher than 5%.

        Exclusion Criteria: Donors

          1. History of psychiatric disorder which may compromise compliance with this protocol or
             which does not allow for appropriate informed consent.

          2. History of hypertension that is not controlled by medication, stroke, or severe heart
             disease (donors with symptomatic angina will be excluded). Donors with a history of
             coronary artery bypass grafting or angioplasty who are symptom free will receive a
             cardiology evaluation and be considered on a case-by-case basis.

          3. Donors must not be pregnant.

          4. Anemia (Hb < 11 gm/dl) or thrombocytopenia (platelets < 100,000 per microL). However,
             potential donors with Hb levels < 11 gm/dl that is due to iron deficiency will be
             eligible as long as the donor is initiated on iron replacement therapy. The NIH
             Clinical Center, Department of Transfusion Medicine/NMDP physicians will determine the
             appropriateness of individuals as donors.